Identifying digital pathology imaging based biomarkers of checkpoint inhibitor response in non-small cell lung cancer

被引：0
|
作者：
Patkar, Sushant
Chen, Alex
Rajendran, Rahul
Basnet, Alina
Turkbey, Baris
Choyke, Peter L.
Harmon, Stephanie A.
Jamaspishvili, Tamara
机构：
[1] NCI, NIH, Bethesda, VA USA
[2] NCI, NIH, Bethesda, MD USA
[3] SUNY Upstate Med Univ, Syracuse, NY USA
[4] NCI, Mol Imaging Branch, NIH, Bethesda, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8530
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Pre- and post-treatment biomarkers for non-small cell lung cancer treated with immune checkpoint inhibitor
    Murata, D.
    Azuma, K.
    Nishii, Y.
    Tokito, T.
    Hoshino, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1333 - S1333
  • [22] Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer
    Weller, A.
    O'Brien, M. E. R.
    Ahmed, M.
    Popat, S.
    Bhosle, J.
    McDonald, F.
    Yap, T. A.
    Du, Y.
    Vlahos, I.
    deSouza, N. M.
    EUROPEAN JOURNAL OF CANCER, 2016, 59 : 65 - 78
  • [23] Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogenedriven resectable non-small cell lung cancer (NSCLC)
    Rosner, Samuel
    Sivapalan, Lavanya
    Zahurak, Marianna
    Thummalapalli, Rohit
    Rayes, Roni
    Connor, Sydney
    Sanber, Khaled
    Reuss, Joshua E.
    Pereira, Gavin
    Smith, Kellie Nicole
    Anagnostou, Valsamo
    Broderick, Stephen
    Jones, David Randolph
    Brahmer, Julie R.
    Marrone, Kristen A.
    Spicer, Jonathan
    Chaft, Jamie E.
    Forde, Patrick M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] A CASE OF IMMUNE CHECKPOINT INHIBITOR ASSOCIATED MYOCARDITIS IN NON-SMALL CELL LUNG CANCER
    Murphy, Andrew
    Ismail, Ali
    Monzer, Nasser
    Sangoi, Matthew
    Khan, Aarish Husain
    Khazan, Benjamin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 3191 - 3191
  • [25] Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer
    Conroy, Michael R.
    Dennehy, Colum
    Forde, Patrick M.
    LUNG CANCER, 2023, 183
  • [26] PATIENT EXPERIENCE OF IMMUNE CHECKPOINT INHIBITOR THERAPY FOR NON-SMALL CELL LUNG CANCER
    Williams, Loretta A.
    Whisenant, Meagan
    Malveaux, Donna
    Singhi, Eric K.
    Altan, Mehmet
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [27] Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer
    Xie, Hao
    Adjei, Alex A.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 : S41 - S43
  • [28] The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer
    Watanabe, Hiromi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kudo, Kenichiro
    Minami, Daisuke
    Murakami, Etsuko
    Ochi, Nobuaki
    Ninomiya, Takashi
    Harada, Daijiro
    Yasugi, Masayuki
    Ichihara, Eiki
    Ohashi, Kadoaki
    Fujiwara, Keiichi
    Hotta, Katsuyuki
    Tabata, Masahiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (08) : 762 - 765
  • [29] Patterns of response and progression with immune-checkpoint inhibitor combinations in advanced non-small cell lung cancer
    Brown, Lauren
    Ahn, Julie
    Gee, Harriet
    Nagrial, Adnan
    Hau, Eric
    Da Silva, Ines Pires
    RESPIROLOGY, 2023, 28 : 18 - 19
  • [30] C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer
    Kluemper, Niklas
    Saal, Jonas
    Berner, Fiamma
    Lichtensteiger, Christa
    Wyss, Nina
    Heine, Annkristin
    Bauernfeind, Franz Georg
    Ellinger, Joerg
    Brossart, Peter
    Diem, Stefan
    Schmid, Sabine
    Joerger, Markus
    Frueh, Martin
    Ritter, Manuel
    Hoelzel, Michael
    Flatz, Lukas
    Bald, Tobias
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
12345